- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 20.02. | Isofol Medical AB: Isofol Medical AB (publ) publishes year-end report, January - December 2023 | 139 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, February 20, 2024 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company's year-end report for January - December 2023 is now available on the company's... ► Artikel lesen | |
| 14.02. | ISOFOL MEDICAL AB: Isofol's Board of Directors decides to initiate the planning of clinical studies and will announce a strategic development plan on March 19 | 1 | Cision News | ||
| 10.01. | ISOFOL MEDICAL AB: Isofol appoints Magnus Hurst as new Chief Financial Officer | 1 | Cision News | ||
| 09.01. | ISOFOL MEDICAL AB: Isofol appoints Petter Segelman Lindqvist as new CEO | 1 | Cision News | ||
| 04.01. | ISOFOL MEDICAL AB: Bulletin from extraordinary general meeting in Isofol Medical AB (publ) held on January 4, 2024 | 1 | Cision News | ||
| 28.12.23 | ISOFOL MEDICAL AB: Isofol presents additional results from laboratory tests with arfolitixorin showing supplementary effects | 2 | Cision News | ||
| 13.12.23 | ISOFOL MEDICAL AB: Isofol's board of directors announces its position on minority shareholder's proposal ahead of extraordinary general meeting | 1 | Cision News | ||
| 07.12.23 | ISOFOL MEDICAL AB: Isofol has received the first results from laboratory tests of arfolitixorin | 1 | Cision News | ||
| 01.12.23 | ISOFOL MEDICAL AB: Isofol is liquidating a subsidiary | 1 | Cision News | ||
| 21.11.23 | ISOFOL MEDICAL AB: Notice convening the Extraordinary General Meeting in Isofol Medical AB (publ) 4 January 2024 | 1 | Cision News | ||
| 09.11.23 | ISOFOL MEDICAL AB: Isofol has obtained a request to call an extraordinary general meeting | 2 | Cision News | ||
| 08.11.23 | ISOFOL MEDICAL AB: Isofol appoints nomination committee ahead of the Annual General Meeting 2024 | 3 | Cision News |
12 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INTELLIA THERAPEUTICS | 19,975 | +0,99 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces First Patient Dosed in the Phase 3 MAGNITUDE Study of NTLA-2001 as a Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy | CAMBRIDGE, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,300 | +2,65 % | PacBio moved to Neutral at JPMorgan after guidance cut | ||
| CENTOGENE | 0,448 | +3,47 % | Centogene NV: CENTOGENE Receives Nasdaq Non-Compliance Notice | CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, April 02, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG) ("Centogene", "we", or the "Company"), the essential life science partner for data-driven... ► Artikel lesen | |
| ATAI LIFE SCIENCES | 1,804 | +2,94 % | atai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate and Clinical Highlights | Strategic investment in Beckley Psytech to accelerate the development of psychedelic-based therapies that fit within the two hour in-clinic treatment paradigm established by Spravato®Initial BPL-003... ► Artikel lesen | |
| BIOMERIEUX | 101,00 | +0,20 % | Biomerieux shares eye best day in 25 mths after better-than-expected Q1 | ||
| CYCLACEL | 1,710 | 0,00 % | Immutep, Capricor Therapeutics, Cyclacel Pharmaceuticals among healthcare movers | ||
| SYROS PHARMACEUTICALS | 5,000 | +5,49 % | Syros Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies... ► Artikel lesen | |
| GENUS | 19,900 | +1,53 % | Dividendenbekanntmachungen (29.02.2024) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ADVANCED DRAINAGE SYSTEMS INC US00790R1041 0,14 USD 0,1291 EUR AGNICO EAGLE MINES LIMITED CA0084741085 0,4 USD 0,369 EUR ALLIANCE... ► Artikel lesen | |
| ATRECA | 0,155 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 28.03.2024 | The following instruments on Boerse Frankfurt do have their last trading day on 28.03.2024Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 28.03.2024ISIN NameGB00BZ2JBG28 REACT... ► Artikel lesen | |
| XTL BIOPHARMACEUTICALS | 2,300 | -2,54 % | XTL BIOPHARMACEUTICALS LTD - 6-K, Report of foreign issuer | ||
| ANAPTYSBIO | 17,900 | -1,10 % | AnaptysBio, Inc.: Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update | Enrollment ongoing for global Phase 2b trial to treat atopic dermatitis (AD) with ANB032, our BTLA agonist, with top-line data anticipated by year-end 2024Enrollment ongoing for global Phase 2b trial... ► Artikel lesen | |
| ABIONYX PHARMA | 0,982 | -0,20 % | ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company's Share Capital | Article L233-8-II of the French Commercial Code Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority)
Regulatory News:
ABIONYX Pharma (Paris:ABNX)
Market:... ► Artikel lesen | |
| MEIRAGTX | 4,480 | -3,03 % | MeiraGTx to Participate in Upcoming Investor Conferences | ||
| METABOLIC EXPLORER | 0,137 | -33,82 % | XFRA 7ME: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| AKESO | 5,450 | +0,93 % | AKESO (09926): VOLUNTARY ANNOUNCEMENT - THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION ACCEPTED THE SUPPLEMENTAL NEW DRUG APPLICATION FOR CADONILIMAB (PD-1/CTLA-4) ... |
Das Unternehmen ISOFOL MEDICAL AB kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,002 (-3,62 %) liegt der Kurs bei 0,045 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
